Genomic Test Spares Millions of Breast Cancer Patients Chemotherapy

A significant breakthrough in breast cancer treatment has emerged from the phase 3 OPTIMA trial, revealing that a genomic test, specifically the Prosigna (PAM50 Risk of Recurrence - ROR) assay, can safely identify a large proportion of patients with early-stage, estrogen receptor (ER)-positive/HER2-negative breast cancer who can effectively avoid chemotherapy. The findings, presented at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, are poised to transform global treatment guidelines and spare millions of individuals the harsh side effects of chemotherapy. The OPTIMA trial, an international study led by University College London, enrolled over 4,400 patients across various countries including the UK, Norway, Sweden, Australia, New Zealand, and Thailand. The study focused on patients aged 40 and over who had high clinical risk, ER-positive/HER2-negative early breast cancer, a subtype that represents the majority of breast cancer cases worldwide. Notably, the trial also included premenopausal women who received ovarian function suppression and patients with up to nine involved lymph nodes, expanding the applicability of genomic testing beyond previously studied populations. The core revelation of the OPTIMA trial is that for approximately two-thirds (68%) of the participants who had a low Prosigna score (ROR ≤ 60), there was no significant additional benefit from chemotherapy when compared to receiving hormone therapy alone. The 5-year invasive breast cancer-free survival (IBCFS) rate was reported to be 93.6%-93.7% for those who opted out of chemotherapy, which was statistically non-inferior to the 94.8%-94.9% rate observed in patients who received chemotherapy alongside hormone therapy. This small difference was deemed clinically insignificant, demonstrating that for this specific patient group, chemotherapy offers little to no meaningful advantage. This breakthrough holds immense promise for breast cancer patients globally. Chemotherapy, while life-saving for many, is associated with a range of debilitating and often long-lasting side effects, including hair loss, nausea, fatigue, nerve damage, infertility, and cognitive impairment. By accurately identifying patients who can safely forgo this aggressive treatment, the Prosigna test enables a more personalized and less toxic therapeutic approach, significantly improving patients' quality of life during and after treatment. The claim that 'millions' of breast cancer patients could benefit from this genomic test is a well-supported projection. Given that ER-positive/HER2-negative breast cancer is the most prevalent form globally, and the Prosigna test can guide treatment decisions for about two-thirds of these patients, the potential impact on worldwide patient populations is indeed substantial. Experts anticipate that these findings will lead to a re-evaluation of standard treatment protocols and broader integration of genomic testing into routine clinical practice. For an audience in India, this news is particularly relevant. Breast cancer is the most common cancer among women in India, with its incidence rates steadily increasing. The healthcare system faces significant challenges, and the ability to tailor treatments based on genomic profiles can lead to more efficient resource allocation and reduced healthcare costs by avoiding unnecessary chemotherapy. Studies have already highlighted the importance and cost-effectiveness of gene expression profiling tests in the Indian context, as they can help identify patients with a favorable prognosis who may safely forego chemotherapy, thereby reducing toxicity and avoidable expenses. The widespread adoption of such tests, coupled with genetic counseling, could significantly improve outcomes and quality of life for Indian breast cancer patients. In conclusion, the OPTIMA trial's results, presented at ASCO 2026, mark a pivotal moment in oncology. The Prosigna genomic test offers a scientifically validated method to de-escalate treatment for a large subset of breast cancer patients, enabling them to avoid chemotherapy without compromising their chances of long-term survival. This advancement ushers in a new era of personalized medicine in breast cancer care with profound global implications, including for countries like India where the burden of this disease is substantial.

Frequently Asked Questions

Read Full Story on Quick Digest